Antibiotics | CHOP Research Institute


Published on
Nov 20, 2023
The NIH-funded study, PRESCRIBE, will help researchers understand how antibiotics affect organ function recovery and respiratory microbiota in children with sepsis.
Published on
Jan 21, 2022
Learn about novel findings and new funding from our Children’s Hospital of Philadelphia researchers.
Published on
Jul 21, 2021
Audrey Odom John, MD, PhD, established a novel approach for developing effective antibiotics that are able to reach resistant bacteria.

The MAGIC Study is looking at the microbiome as it develops during the first two years of life. It brings together expertise in the microbiome, antibiotic stewardship, immunology, neonatology, and infectious diseases to study the effect that health and environment have on the microbiome and growth.

Vancomycin is a commonly administered antibiotic in critically ill children, but it can have unwanted side effects on the kidney (acute kidney injury).

The purpose of this study is to determine how what you eat and drink (your diet), antibiotics you take, and the bacteria that live in your gut (microbiome) contribute to developing kidney stones.

The Downes Lab studies pediatric antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) and pharmacoepidemiology with a focus on the relationship between antibiotic dosing/exposures and outcomes, including clinical cure, adverse events, and the development of antimicrobial resistance.

Published on
Jan 25, 2019
From stem cell fertility research to staying alert for teen suicidal thoughts, this week’s research headlines spark conversations in the news.

The research interests of Dr. Downes focus on antimicrobial clinical pharmacology and pharmacoepidemiology in children with a goal to identify novel approaches to optimize efficacy, minimize toxicity, and limit antimicrobial resistance from antibiotics.

downeskj [at]

Dr. Gmuca seeks to enhance the care of children with chronic musculoskeletal pain. Her current research addresses amplified musculoskeletal pain syndrome, which is a major public health issue because of its high prevalence, related socioeconomic burden, and associated risk of opioid exposure. Dr. Gmuca’s work aims to identify innovative strategies to improve long-term treatment outcomes for this patient population.

gmucas [at]